Cross-sectional Study of Vitamin B6 in Parkinson’s Disease

by palligoelme@gmail.com | Feb 24, 2026 | Clinical Trials

​ Conditions: Parkinson’s Disease (PD) Sponsors: University of Rochester Completed Conditions: Parkinson’s Disease (PD) Sponsors: University of Rochester Completed 

Benefits of Physical Activity During the School Day to Reduce Mental Fatigue and Optimize Cognitive and Psychosocial Processes in Secondary School Students

by palligoelme@gmail.com | Feb 23, 2026 | Clinical Trials

​ Conditions: Mental Fatigue; Adolescent Behavior; Physical Inactivity Interventions: Behavioral: Active breaks; Behavioral: Physically active learning; Behavioral: Active Recess Sponsors: University of Extremadura; Ministerio de Ciencia, Innovación y Universidades,...

Chronic Pain After Combat-Related Traumatic Brain Injury (cTBI-Pain Study) A Prospective Cohort Study of Pain Chronification After Combat-Related Traumatic Brain Injury

by palligoelme@gmail.com | Feb 23, 2026 | Clinical Trials

​ Conditions: Pain; Chronic Pain; Chronic Pain Due to Injury Sponsors: Charitable Organisation Charitable Fund Superhumans (Co Cf Superhumans) Not yet recruiting Conditions: Pain; Chronic Pain; Chronic Pain Due to Injury Sponsors: Charitable Organisation Charitable...

Analysis of Cutaneous Phosphorylated Alpha-Synuclein to Identify Patients at Risk of Progressing From Essential Tremor to Parkinson’s Disease

by palligoelme@gmail.com | Feb 23, 2026 | Clinical Trials

​ Conditions: Essential Tremor, Movement Disorders; Essential Tremor; Essential Tremor-plus Sponsors: CND Life Sciences; National Institute of Neurological Disorders and Stroke (NINDS) Recruiting Conditions: Essential Tremor, Movement Disorders; Essential Tremor;...

Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)

by palligoelme@gmail.com | Feb 23, 2026 | Clinical Trials

​ Conditions: Hereditary Angioedema (HAE); Hereditary Angioedema – Type 1; Hereditary Angioedema – Type 2; HAE Interventions: Drug: ADX-324 Dose Level 1; Drug: ADX-324 Dose Level 2 Sponsors: ADARx Pharmaceuticals, Inc. Not yet recruiting Conditions:...

Resilience-Building for Advance Care Planning

by palligoelme@gmail.com | Feb 23, 2026 | Clinical Trials

​ Conditions: Advanced Cancer; End of Life Interventions: Behavioral: ROCKS; Behavioral: Usual Care Sponsors: University of Illinois at Chicago; National Institute of Nursing Research (NINR) Not yet recruiting Conditions: Advanced Cancer; End of Life Interventions:...